Stage 2 of trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.
STREAM Stage 2 Trial will evaluate simpler and shorter treatment regimens for patients with multidrug-resistant tuberculosis (MDR-TB). The current treatment standard for MDR-TB involves a complex regime that can last up to 24 months.
The study will include bedaquiline to test its effectiveness within a shortened MDR-TB treatment regimen - an all-oral 9-month regimen and a 6-month regimen.
To read the full press release, click here.
Source: The Union